Navigation Links
Orexigen® Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave® in North America
Date:9/2/2010

Takeda for aspects of the development and commercialization of Contrave; the potential for the FDA to delay the scheduled PDUFA action date of January 31, 2011 due to the FDA's internal resource constraints or other reasons; the uncertainty of the FDA approval process and other regulatory requirements; the FDA may not agree with the Company's interpretation of efficacy and safety results; the FDA may require Orexigen to complete additional clinical, non-clinical or other requirements prior to the approval of the Contrave NDA; the therapeutic and commercial value of Contrave; reliance on third parties to assist with the development of Contrave and the regulatory submissions related thereto; the potential for adverse safety findings relating to Contrave; and other risks described in the Company's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included under the heading "Risk Factors" in Orexigen's Quarterly Report on Form 10-Q, which was filed with the Securities Exchange Commission on August 6, 2010 and is available from the SEC's website (www.sec.gov) and on our website (www.orexigen.com) under the heading "Investor Relations". All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

Forward-Looking Statements Related to Takeda

This press release contains forward-looking statements regarding the Company's plans, outlook, strategies, and results for the future.  All forward-looki
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Orexigen® Therapeutics COR-BMOD Study Published in the Journal Obesity
2. Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
3. Orexigen® Therapeutics Schedules August 5, 2010 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2010
4. Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity
5. Reportlinker Adds Urological Disorders Therapeutics to 2016 - Increasing Awareness and Aging Population will Drive the Benign Prostatic Hyperplasia and Urinary Incontinence Markets
6. Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
7. Echo Therapeutics Announces Successful Completion of Clinical Trial for Prelude™ SkinPrep System and 4% Lidocaine Cream
8. BioMarin Acquires ZyStor Therapeutics, Inc.
9. Nile Therapeutics Reports 2010 Second Quarter Financial Results
10. Cornerstone Therapeutics Announces Development of Generic for Tussionex®
11. Cornerstone Therapeutics Licenses Alpha-7 Technology to Targacept
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 19, 2014  Advanced Medical Isotope Corporation ("AMIC") ... primarily in the development of brachytherapy devices and ... announced that a Life Sciences Discovery Fund (LSDF) ... which AMIC is the commercialization partner.  The award ... the proposal titled "Optimized Injectable Radiogels for High-dose ...
(Date:12/19/2014)... WESTMINSTER, Colo. , Dec. 19, 2014  Monarch ... (f/k/a Cannabis Kinetics Corp.) is pleased to provide this ... for continued growth in 2015. "Over this ... corporate goals and I am extremely proud to say ... diversified position today than it has ever been," stated ...
(Date:12/19/2014)... , Dec. 18, 2014  Sage Analytics ... generation of equipment for the testing of marijuana ... of the new Luminary™ Profiler, the industry,s first ... measurement in a cost-effective, portable unit. ... specific needs of the cannabis industry, the Luminary™ ...
Breaking Medicine Technology:Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 2Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 3Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 3Sage Analytics Develops Breakthrough System for Potency Testing of Cannabis Products 2
... symptom control ... with combination therapy ... published study presents,data demonstrating that patients with Chronic Obstructive ... bronchodilation and symptom control when treated with a,combination of ...
... a Benefit,of Anti-Tumor Necrosis Factor Therapies on Absenteeism Among Employees with ... ... a new analysis of the,Active Ulcerative Colitis Trials (ACT 1 and ... patients with moderately to severely active,ulcerative colitis (UC) receiving REMICADE(R) (infliximab) ...
Cached Medicine Technology:Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 2Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 3Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 4Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 5Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 6Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 7New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 2New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 3New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 4New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 5New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 6New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 7New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 8
(Date:12/20/2014)... Recently, VogueQueen.com, a leading wedding dress wholesaler ... Online for 2015. Great discounts are now offered ... consumers can get a discount, up to 80% off, ... before January 30, 2015. , VogueQueen.com has recently released ... prom dress promotion. Many customers worldwide like VogueQueen’s special ...
(Date:12/20/2014)... Angeldress.co.uk, the distinguished wedding dress manufacturer ... dress fans. The company has recently updated its official ... the holiday season, Angeldress Blog has recommended ... , Angeldress.co.uk prides itself in offering a huge selection ... All the company’s outfits are very carefully selected based ...
(Date:12/20/2014)... Atore, Inc, (San Francisco, CA CEO: Masashi ... focused portal on December 17th, 2014. , One ... US and Japan. , MERRY BIRTHDAY SITE : ... , MERRY BIRTHDAY MESSAGE is part of 5 future ... Features, Choose from thousands of stock photos to decorate ...
(Date:12/20/2014)... Recently, AngelWeddingDress.com has introduced its special offer ... coming Christmas. In the promotion, all buyers worldwide can ... have something special for the women who are looking ... our new collections of 2015 dresses have been unveiled ... greatly discounted prices. Visit our website now before they ...
(Date:12/20/2014)... (PRWEB) December 20, 2014 Xarelto ... they suffered uncontrollable bleeding and other serious side ... Eastern District of Louisiana for coordinated pretrial proceedings, Wright ... Multidistrict Litigation (JPML) issued an order Friday to transfer ... pending in 22 federal courts to the Louisiana district ...
Breaking Medicine News(10 mins):Health News:VogueQueen Big Sale Online For The Coming 2015 2Health News:Trendy Professional Wedding Apparel Recommended by Angeldress Blog 2Health News:Atore, Inc. Releasing the First Birthday Portal 2Health News:AngelWeddingDress Has Introduced Its Special Offer For The Coming Christmas 2Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 2Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 3Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 4
... to therapeutic applications in humans, researchers say ... neurons derived from reprogrammed adult skin cells successfully ... reduced symptoms of a Parkinson,s disease-like condition in ... the first demonstration that reprogrammed cells can integrate ...
... 7, 2008 , WHEN: Lecture: Thursday, April 10, 2008 from 1:30 ... interviews with spokespeople available before and ... to schedule., WHERE: The University of Texas at Austin ... 2405 Robert Dedman Drive ...
... new study says , , MONDAY, April 7 (HealthDay News) ... drugs, accidental overdoses and unfavorable reactions -- affect about ... study says. , That figure is much higher than ... errors involving hospitalized children -- an issue that generated ...
... 2008 Looking for new,ideas for a Mother,s Day ... Day MiniWeek from May 11 - 15, 2008, Deerfield ... everyone in their,party, and offering complimentary make-up applications prior ... will receive $200 each,towards spa services during their stay., ...
... Stronger than anticipated,revenues for flu vaccines, and the surprising ... cervical cancers, has led to a healthy,$16.3 billion in ... 38%,over 2006 sales of $11.7 billion, according to Vaccines ... a Fast-Changing Industry, a,new market research study and reforecast ...
... April 7, 2008 Forest Laboratories,Inc. (NYSE: ... products, will release its Fiscal 2008 Fourth Quarter,financial ... Tuesday, April 15,2008. Later that day, at 10:00 ... Dr. Lawrence Olanoff, President and Chief Operating Officer ...
Cached Medicine News:Health News:Reprogrammed Cells Reduce Parkinson's Symptoms 2Health News:Childhood Obesity Expert Dr. William Dietz Featured at the 2nd Annual Michael & Susan Dell Lectureship in Child Health 2Health News:Childhood Obesity Expert Dr. William Dietz Featured at the 2nd Annual Michael & Susan Dell Lectureship in Child Health 3Health News:Childhood Obesity Expert Dr. William Dietz Featured at the 2nd Annual Michael & Susan Dell Lectureship in Child Health 4Health News:Drug Mix-Ups Harm Hospitalized Kids 2Health News:Drug Mix-Ups Harm Hospitalized Kids 3Health News:Mother's Day Gifts from Deerfield Spa Give Moms What They Love Most ... Photographs and Memories 2Health News:Gardasil, Other New Products Spur Strong Vaccine Sales in 2007 2Health News:Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2008 Fourth Quarter Earnings 2
... tip is specially rounded, extra ... wound and manipulation in the ... flexible tubing 25cm, ID - ... annular rings start .85mm ...
For administering anesthetic agents into the posterior sub-Tenon's space 20G x 1in (.90 x 25mm)...
... This all digital single plane C-arm angiography ... cardiac imaging performance and an expansive range ... cardiac angiography to ECG triggered. ... Detector technology,State of the art dynamic Flat ...
For diagnostic and operative treatment of hand and wrist bones. The use of this distraction device allows fracture reduction or widening of the space between bones....
Medicine Products: